{"id":"tp-53747","type":"article-newspaper","title":"FDA Requires Vision-Risk Warnings Across the GLP-1 Drug Class","author":"Riza Dagoc","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/regulation/53747","datePublished":"2026-11-11T09:25:16.000Z","dateModified":"2026-11-11T09:25:16.000Z","language":"en","abstract":"A review found 15 probable cases among 134,253 trial participants. A separate analysis found mixed results when comparing GLP-1 drugs with other diabetes treatments.","section":"Regulation","references":[]}